Notes
National Health Service
Reference
McKee S. NICE backs Merck's Mavenclad for MS Pharma Times : 10 Nov 2017. Available from: URL: http://www.pharmatimes.com/news/nice_backs_mercks_mavenclad_for_ms_1210957
Rights and permissions
About this article
Cite this article
NICE recommending cladribine for severe active RRMS. PharmacoEcon Outcomes News 791, 37 (2017). https://doi.org/10.1007/s40274-017-4521-7
Published:
Issue Date:
DOI: https://doi.org/10.1007/s40274-017-4521-7